A medical records based study for the preliminary efficacy of Tocilizumab in the treatment of the patients with novel coronavirus pneumonia (COVID-19)

Preliminary efficacy of Tocilizumab in the treatment of the patients with novel coronavirus pneumonia (COVID-19)

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2000033705

Enrollment

Unknown

Registered

2020-06-10

Start date

2020-02-27

Completion date

Unknown

Last updated

2020-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Novel Coronavirus Pneumonia (COVID-19)

Interventions

Tocilizumab:Tocilizumab

contral:routine treatment protocol

Eligibility

Sex/Gender

Male

Age

18 Years to 110 Years

Inclusion criteria

Inclusion criteria: (1) Diagnosed as COVID-19; (2) aged > 18 years old; (3) IL-6 level > 7 pg/mL.

Exclusion criteria

Exclusion criteria: (1) Pregnant or lactating women; (2) Alanine transaminase (ALT)/ Aspartate transaminase (AST) > five times ULN, neutrophil < 0.5x10^9/l, platelet <50x 10^9/l; (3) Diagnosis of rheumatism immunity, malignant tumor, and other related diseases; (4) Long-term oral administration of anti-rejection drugs or immunomodulatory drugs; (5) Allergic reaction to Tocilizumab or any auxiliary materials; (6) Active hepatitis, tuberculosis; (7) Patients received organ transplantation; (8) Mental disorders.

Design outcomes

Primary

Measure	Time frame
clinical manifestations;laboratory examination;	—

Countries

China

Contacts

Public ContactXijing Zhang

Department of Critical Care Medicine, Xijing Hospital, Air Force Military Medical University

zhangxj918@163.com+86 13384920881

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026